A constellation of complications: The metabolic syndrome

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The metabolic syndrome is a common cluster of risk factors for coronary heart disease and type 2 diabetes mellitus that includes obesity, elevated blood pressure, insulin resistance, and dyslipidemia. The diagnosis of metabolic syndrome itself appears to be an important risk factor for atherogenic cardiovascular disease and diabetes, and there is recent evidence that its components cluster, rather than occurring together by coincidence. A recent statement from the American Heart Association and the National Heart, Lung, and Blood Institute slightly modifies and clarifies the diagnostic criteria for the metabolic syndrome that are most widely used in the United States, along with giving practical guidance about management. Prompt therapeutic attention to the underlying risk factors - abdominal obesity, physical inactivity, and atherogenic/diabetogenic diet - is warranted for all patients with the metabolic syndrome, and drug therapy for specific metabolic risk factors should be considered for those at high or moderately high 10-year absolute risk of atherosclerotic cardiovascular disease. A new class of investigational drugs that block cannabinoid type 1 receptors have shown promise. This review also discusses issues that require additional research and new drugs that are considered promising for treatment of the metabolic syndrome itself.

Original languageEnglish (US)
Pages (from-to)36-45
Number of pages10
JournalClinical Cornerstone
Volume7
Issue number2-3
DOIs
StatePublished - 2005

Fingerprint

Cardiovascular Diseases
Investigational Drugs
Atherogenic Diet
National Heart, Lung, and Blood Institute (U.S.)
Cannabinoid Receptors
Abdominal Obesity
Dyslipidemias
Type 2 Diabetes Mellitus
Coronary Disease
Insulin Resistance
Obesity
Blood Pressure
Drug Therapy
Therapeutics
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A constellation of complications : The metabolic syndrome. / Grundy, Scott M.

In: Clinical Cornerstone, Vol. 7, No. 2-3, 2005, p. 36-45.

Research output: Contribution to journalArticle

@article{eebaf8f038df45f08dfa0a738d1233ab,
title = "A constellation of complications: The metabolic syndrome",
abstract = "The metabolic syndrome is a common cluster of risk factors for coronary heart disease and type 2 diabetes mellitus that includes obesity, elevated blood pressure, insulin resistance, and dyslipidemia. The diagnosis of metabolic syndrome itself appears to be an important risk factor for atherogenic cardiovascular disease and diabetes, and there is recent evidence that its components cluster, rather than occurring together by coincidence. A recent statement from the American Heart Association and the National Heart, Lung, and Blood Institute slightly modifies and clarifies the diagnostic criteria for the metabolic syndrome that are most widely used in the United States, along with giving practical guidance about management. Prompt therapeutic attention to the underlying risk factors - abdominal obesity, physical inactivity, and atherogenic/diabetogenic diet - is warranted for all patients with the metabolic syndrome, and drug therapy for specific metabolic risk factors should be considered for those at high or moderately high 10-year absolute risk of atherosclerotic cardiovascular disease. A new class of investigational drugs that block cannabinoid type 1 receptors have shown promise. This review also discusses issues that require additional research and new drugs that are considered promising for treatment of the metabolic syndrome itself.",
author = "Grundy, {Scott M}",
year = "2005",
doi = "10.1016/S1098-3597(05)80066-3",
language = "English (US)",
volume = "7",
pages = "36--45",
journal = "Clinical Cornerstone",
issn = "1098-3597",
publisher = "Excerpta Medica",
number = "2-3",

}

TY - JOUR

T1 - A constellation of complications

T2 - The metabolic syndrome

AU - Grundy, Scott M

PY - 2005

Y1 - 2005

N2 - The metabolic syndrome is a common cluster of risk factors for coronary heart disease and type 2 diabetes mellitus that includes obesity, elevated blood pressure, insulin resistance, and dyslipidemia. The diagnosis of metabolic syndrome itself appears to be an important risk factor for atherogenic cardiovascular disease and diabetes, and there is recent evidence that its components cluster, rather than occurring together by coincidence. A recent statement from the American Heart Association and the National Heart, Lung, and Blood Institute slightly modifies and clarifies the diagnostic criteria for the metabolic syndrome that are most widely used in the United States, along with giving practical guidance about management. Prompt therapeutic attention to the underlying risk factors - abdominal obesity, physical inactivity, and atherogenic/diabetogenic diet - is warranted for all patients with the metabolic syndrome, and drug therapy for specific metabolic risk factors should be considered for those at high or moderately high 10-year absolute risk of atherosclerotic cardiovascular disease. A new class of investigational drugs that block cannabinoid type 1 receptors have shown promise. This review also discusses issues that require additional research and new drugs that are considered promising for treatment of the metabolic syndrome itself.

AB - The metabolic syndrome is a common cluster of risk factors for coronary heart disease and type 2 diabetes mellitus that includes obesity, elevated blood pressure, insulin resistance, and dyslipidemia. The diagnosis of metabolic syndrome itself appears to be an important risk factor for atherogenic cardiovascular disease and diabetes, and there is recent evidence that its components cluster, rather than occurring together by coincidence. A recent statement from the American Heart Association and the National Heart, Lung, and Blood Institute slightly modifies and clarifies the diagnostic criteria for the metabolic syndrome that are most widely used in the United States, along with giving practical guidance about management. Prompt therapeutic attention to the underlying risk factors - abdominal obesity, physical inactivity, and atherogenic/diabetogenic diet - is warranted for all patients with the metabolic syndrome, and drug therapy for specific metabolic risk factors should be considered for those at high or moderately high 10-year absolute risk of atherosclerotic cardiovascular disease. A new class of investigational drugs that block cannabinoid type 1 receptors have shown promise. This review also discusses issues that require additional research and new drugs that are considered promising for treatment of the metabolic syndrome itself.

UR - http://www.scopus.com/inward/record.url?scp=32144448122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144448122&partnerID=8YFLogxK

U2 - 10.1016/S1098-3597(05)80066-3

DO - 10.1016/S1098-3597(05)80066-3

M3 - Article

C2 - 16473259

AN - SCOPUS:32144448122

VL - 7

SP - 36

EP - 45

JO - Clinical Cornerstone

JF - Clinical Cornerstone

SN - 1098-3597

IS - 2-3

ER -